PEB to Participate in Upcoming Investor Conferences

14/09/2026 12:16 NZST, GENERALP

PACIFIC EDGE TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

DUNEDIN, New Zealand – Pacific Edge (NZX/ASX: PEB) announces that it will participate in several upcoming investor conferences across Australia and New Zealand in the coming weeks.

• New Zealand Shareholders Association’s The Horizon for Healthcare, Auckland, September 16

• Evans and Partners Small Cap Healthcare Conference, Sydney, September 16

• ASX SMIDcaps, Sydney, September 23

• NZX Tech Investor Day, Auckland, October 8

• Bell Potter Healthcare, Virtual, November 17

Pacific Edge has revised its corporate presentation for those activities and is making new slides available on the NZX and ASX. The presentation is also available on Pacific Edge’s investor website.

ENDS

For more information:

Investors:

Dr Peter Meintjes

Chief Executive

Pacific Edge

P: +64 22 032 1263

Media:

Richard Inder

The Project

P: +64 21 645 643

OVERVIEW

Pacific Edge: www.pacificedgedx.com

Pacific Edge Limited (NZX/ ASX: PEB) is a global cancer diagnostics company leading the way in the development and commercialization of bladder cancer diagnostic and prognostic tests for patients presenting with hematuria or surveillance of recurrent disease. Headquartered in Dunedin, New Zealand, the company provides its suite of Cxbladder tests globally through its wholly owned, and CLIA certified, laboratories in New Zealand and the USA.

Cxbladder: www.cxbladder.com

Cxbladder is a suite of non-invasive genomic urine tests optimized for the risk stratification of urothelial cancer in patients presenting with hematuria and those being monitored for recurrent disease. The tests help improve the overall patient experience, while prioritizing time and clinical resources to optimize practice workflow and improve efficiency.

Supported by over 20 years of research, Cxbladder’s evidence portfolio extends to more than twenty-five peer reviewed publications, and Cxbladder Triage is now included in the American Urological Association’s Microhematuria Guideline. To drive increased adoption and improved patient health outcomes, Cxbladder is the focal point of numerous ongoing and planned studies designed to generate further clinical utility evidence.

Cxbladder is available in the US, Australasia, and Israel and in markets throughout Asia and South America. In the US, the test has been used by over 5,000 urologists who have ordered more than 130,000 tests. In New Zealand, Cxbladder is accessible to around 70% of the population via public healthcare and all residents have the option of buying the test online.